Defendant

Conjupro Biotherapeutics, Inc.

3 cases as defendant.

Cases
3
Active
2
1 closed
Filed
2024–2025
Top venue
D. New Jersey
2 cases
Also appears as a plaintiff in 1 case → View as plaintiff

Company profile

CONJUPRO BIOTHERAPEUTICS, INC. is a biopharmaceutical company headquartered in Princeton, New Jersey, founded in 2017. It operates as a subsidiary of CSPC Pharmaceutical Group Limited ("CSPC"), a large Chinese pharmaceutical company listed on the Hong Kong Stock Exchange (1093.HK). The company employs between 10 and 50 individuals.

Conjupro Biotherapeutics focuses on preclinical and clinical research and development, providing diversified R&D solutions. Its primary areas of therapeutic focus include oncology, cardiology, and central nervous system (CNS) diseases, with the goal of developing new medicines. The company also engages in drug discovery and clinical development, recently celebrating its first New Drug Approval in the USA.

According to the authoritative case data, CONJUPRO BIOTHERAPEUTICS, INC. has been involved in one tracked patent litigation case as a plaintiff and zero as a defendant. This indicates an active posture in managing its intellectual property. The single tracked case, CONJUPRO BIOTHERAPEUTICS, INC. v. Ascletis Pharma China Co Ltd, is a Post-Grant Review (PGR) proceeding initiated at the Patent Trial and Appeal Board (PTAB) on June 20, 2025. In this proceeding, Conjupro is challenging a patent held by Ascletis Pharma China Co Ltd, which is typical for an operating company actively navigating the patent landscape to protect its market interests or clear potential obstacles for its products.

Filing activity

2024: 2 cases2'242025: 1 case'25
Cases filed per year naming Conjupro Biotherapeutics, Inc. as defendant.

Ipsen Biopharmaceuticals, Inc. et al. v. Conjupro Biotherapeutics, Inc. et al.

consolidated; administratively terminated as standalone docket; pending in consolidated action
Docket:
1:25-cv-13647
Filed:
2025-07-22
Terminated:
2025-09-05
Patents:12364691
π Ipsen Biopharmaceuticals, Inc.π Ipsen Biopharm Ltd.Δ Conjupro Biotherapeutics, Inc.Δ CSPC Pharmaceutical Group LimitedΔ CSPC Ouyi Pharmaceutical Co., Ltd.

Ipsen sued Conjupro and CSPC defendants in the District of New Jersey for infringement of U.S. Patent No. 12,364,691 under 35 U.S.C. § 271 based on Conjupro's proposed irinotecan liposome injection (generic Onivyde), NDA No. 218923. The case was consolidated with Docket No. 24-4991, and the 25-13647 docket was administratively terminated on September 5, 2025; the '691 claims proceed in the consolidated action.

Ipsen Biopharmaceuticals, Inc. et al. v. Conjupro Biotherapeutics, Inc. et al.

consolidated; administratively terminated
Docket:
1:24-cv-08723
Filed:
2024-08-23
Terminated:
2024-10-18
Patents:12059497
π Ipsen Biopharmaceuticals, Inc.π Ipsen Biopharm Ltd.Δ Conjupro Biotherapeutics, Inc.Δ CSPC Pharmaceutical Group LimitedΔ CSPC Ouyi Pharmaceutical Co., Ltd.

Ipsen asserted U.S. Patent No. 12,059,497 under 35 U.S.C. § 271(e)(2)(A) against Conjupro/CSPC based on NDA No. 218923 for irinotecan liposome injection. The case was consolidated into 1:24-cv-04991 on October 18, 2024 for all purposes and administratively terminated; the consolidated action remains pending in discovery.

Ipsen Biopharmaceuticals, Inc. et al. v. Conjupro Biotherapeutics, Inc. et al.

pending; discovery
Docket:
1:24-cv-04991
Filed:
2024-04-15
Patents:109939148329213933949793644739452162949244297177241098079511369597
π Ipsen Biopharmaceuticals, Inc.π Ipsen Biopharm Ltd.Δ Conjupro Biotherapeutics, Inc.Δ CSPC Pharmaceutical Group LimitedΔ CSPC Ouyi Pharmaceutical Co., Ltd.

Lead consolidated patent infringement action concerning an ANDA/505(b)(2) NDA No. 218923 for generic Onivyde. The complaint affirmatively asserts multiple patents, and US 10,993,914 is in the case through Conjupro/CSPC's declaratory-judgment counterclaims based on a Paragraph IV certification.